This is the authors' abstract. We don't add key points for this paper.
The subcutaneous administration of recombinant human interleukin-1 beta (rhIL-1 beta) was found to induce an increased incidence and earlier onset of collagen-induced arthritis in mice. 2. The rhIL-1 beta had different effects, depending on when it was administered after collagen-immunization. 3. The effect of rhIL-1 beta may be due, in part, to augmentation of the immune response to type II collagen. 4. Interleukin-1-accelerated, collagen-induced arthritis will provide a useful model for investigating the role of interleukin-1 in the regulation of arthritic diseases, and the development of anti-arthritic therapeutics.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Killar et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: